文献速递淋巴瘤

ZUMA-5(阿基仑赛)对比SCHOLAR-5外部对照在复发/难治性滤泡性淋巴瘤中的比较有效性

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
PubMed 文献 · Blood · 2022-01-01

本研究将ZUMA-5试验中阿基仑赛治疗复发/难治性滤泡性淋巴瘤的结果与模拟ZUMA-5入组标准的国际SCHOLAR-5队列进行比较。经倾向评分加权后,SCHOLAR-5有效样本85例,ZUMA-5为86例。阿基仑赛组的总生存和无进展生存均优于SCHOLAR-5,总缓解率和完全缓解率也更高。

要点

  • SCHOLAR-5中位总生存59.8个月,ZUMA-5未达到,风险比为0.42(95%CI 0.21-0.83)。
  • SCHOLAR-5中位无进展生存12.7个月,ZUMA-5未达到,风险比为0.30(95%CI 0.18-0.49)。
  • SCHOLAR-5总缓解率49.9%、完全缓解率29.9%,ZUMA-5分别为94.2%和79.1%。

核心结论

  • 与现有疗法相比,阿基仑赛在具有临床意义的终点上显示出改善,提示其满足了复发/难治性滤泡性淋巴瘤患者的重要未满足需求。

研究设计与样本

  • ZUMA-5为关键性试验,其结局与采用ZUMA-5关键入组标准模拟随机对照试验条件的国际SCHOLAR-5队列进行比较。
  • SCHOLAR-5数据来自5个国家的机构及1项历史临床试验,纳入2014年7月后启动三线或以上治疗的复发/难治性滤泡性淋巴瘤患者。
  • 通过倾向评分对预设预后因素进行标准化死亡比(SMR)加权平衡患者特征,采用加权Kaplan-Meier分析评价时间至事件结局,采用加权比值比比较总缓解率和完全缓解率。
  • SCHOLAR-5的143例患者经SMR加权后有效样本为85例,ZUMA-5为86例。
  • SCHOLAR-5和ZUMA-5的中位随访时间分别为25.4个月和23.3个月。

主要发现

  • SCHOLAR-5中位总生存为59.8个月,ZUMA-5未达到,风险比为0.42(95%CI 0.21-0.83)。
  • SCHOLAR-5中位无进展生存为12.7个月,ZUMA-5未达到,风险比为0.30(95%CI 0.18-0.49)。
  • SCHOLAR-5总缓解率为49.9%、完全缓解率为29.9%,ZUMA-5分别为94.2%和79.1%,比值比分别为16.2(95%CI 5.6-46.9)和8.9(95%CI 4.3-18.3)。

临床怎么用

  • 原文结论指出,与现有疗法相比,阿基仑赛在具有临床意义的终点上显示出改善,提示其满足了复发/难治性滤泡性淋巴瘤患者的重要未满足需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international SCHOLAR-5 cohort, which applied key ZUMA-5 trial eligibility criteria simulating randomized controlled trial conditions. SCHOLAR-5 data were extracted from institutions in 5 countries, and from 1 historical clinical trial, for r/r FL patients who initiated a third or higher line of therapy after July 2014. Patient characteristics were balanced through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. Time-to-event outcomes were evaluated using weighted Kaplan-Meier analysis. Overall response rate (ORR) and complete response (CR) rate were compared using weighted odds ratios. The 143 ScHOLAR-5 patients reduced to an effective sample of 85 patients after SMR weighting vs 86 patients in ZUMA-5. Median follow-up time was 25.4 and 23.3 months for SCHOLAR-5 and ZUMA-5. Median overall survival (OS) and progression-free survival (PFS) in SCHOLAR-5 were 59.8 months and 12.7 months and not reached in ZUMA-5. Hazard ratios for OS and PFS were 0.42 (95% confidence interval [CI], 0.21-0.83) and 0.30 (95% CI, 0.18-0.49). The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 and 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95% CI, 5.6-46.9) and 8.9 (95% CI, 4.3-18.3). Compared with available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints, suggesting axi-cel addresses an important unmet need for r/r FL patients. This trial was registered at www.clinicaltrials.gov as #NCT03105336.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghione P, Palomba ML, Patel AR, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022. PMID: 35679476. doi:10.1182/blood.2021014375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。